Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros


Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 126(3): 482-7, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11737066

RESUMO

A range of strategies are being explored to develop more effective vaccines against mycobacterial infection, including immunization with DNA plasmids encoding single mycobacterial bacterial genes and the use of recombinant live vectors based on the current vaccine, Mycobacterium bovis bacille Calmette-Guérin (BCG). We have compared these two approaches using a model of virulent M. avium infection, and the gene for the immunodominant 35 kDa protein which is shared by M. avium and M. leprae, but absent from BCG. Recombinant BCG over-expressing the M. avium 35 kDa protein (BCG-35) induced strong antigen-specific proliferative and interferon-gamma (IFN-gamma)-secreting T cell responses. These were comparable to those induced by a single immunization with a plasmid expressing the same antigen (DNA-35); however, repeat DNA-35 immunization evoked the strongest IFN-gamma release. Immunization with BCG-35 significantly reduced the growth of virulent M. avium, although this effect was similar to that induced by wild-type BCG. Immunization with DNA-35 resulted in significantly greater (2 x log(10)) reduction in the growth of M. avium. Prime-boost strategies combining DNA-35 and BCG-35 increased the protective effect above that achieved by BCG-35, but they were not more protective than DNA-35 alone. Therefore, recombinant BCG-35 and BCG induced similar levels of protection in this model, and maximal protection against M. avium infection was attained by immunization with DNA encoding the 35 kDa protein.


Assuntos
Vacina BCG/farmacologia , Mycobacterium avium , Tuberculose/prevenção & controle , Vacinas de DNA/farmacologia , Animais , Antígenos de Bactérias/química , Antígenos de Bactérias/genética , Vacina BCG/genética , Feminino , Genes Bacterianos , Interferon gama/biossíntese , Camundongos , Camundongos Endogâmicos C57BL , Peso Molecular , Mycobacterium avium/genética , Mycobacterium avium/imunologia , Mycobacterium avium/patogenicidade , Mycobacterium leprae/genética , Mycobacterium leprae/imunologia , Tuberculose/imunologia , Vacinas de DNA/genética
2.
Infect Immun ; 68(6): 3090-6, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10816448

RESUMO

Mycobacterium avium is an opportunistic pathogen that primarily infects immunocompromised individuals, although the frequency of M. avium infection is also increasing in the immunocompetent population. The antigen repertoire of M. avium varies from that of Mycobacterium tuberculosis, with the immunodominant 35-kDa protein being present in M. avium and Mycobacterium leprae but not in members of the M. tuberculosis complex. Here we show that a DNA vector encoding this M. avium 35-kDa antigen (DNA-35) induces protective immunity against virulent M. avium infection, and this protective effect persists over 14 weeks of infection. In C57BL/6 mice, DNA vaccines expressing the 35-kDa protein as a cytoplasmic or secreted protein, both induced strong T-cell gamma interferon (IFN-gamma) and humoral immune responses. Furthermore, the antibody response was to conformational determinants, confirming that the vector-encoded protein had adopted the native conformation. DNA-35 immunization resulted in an increased activated/memory CD4(+) T-cell response, with an accumulation of CD4(+) CD44(hi) CD45RB(lo) T cells and an increase in antigen-specific IFN-gamma production. The protective effect of the DNA-35 vectors against M. avium infection was comparable to that of vaccination with Mycobacterium bovis BCG and significantly greater than that for previous treated infection with M. avium. These results illustrate the importance of the 35-kDa protein in the protective response to M. avium infection and indicate that DNA vaccination successfully promotes a sustained level of protection during chronic M. avium infection.


Assuntos
Antígenos de Bactérias , Vacina BCG/uso terapêutico , Proteínas de Bactérias/uso terapêutico , Mycobacterium avium/imunologia , Tuberculose/prevenção & controle , Vacinas de DNA/uso terapêutico , Animais , Proteínas de Bactérias/genética , Linfócitos T CD4-Positivos/imunologia , Citocinas/biossíntese , Feminino , Receptores de Hialuronatos/isolamento & purificação , Interferon gama/biossíntese , Antígenos Comuns de Leucócito/isolamento & purificação , Ativação Linfocitária , Camundongos , Camundongos Endogâmicos C57BL , Baço/citologia , Baço/imunologia , Linfócitos T Auxiliares-Indutores , Vacinação
3.
Lepr Rev ; 71 Suppl: S176-81, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11201878

RESUMO

We have investigated the effect of subunit vaccines against infection with Mycobacterium leprae, employing DNA plasmids as the vaccine vectors, and the immunodominant 35 kDa protein of M. leprae as the candidate antigen. A DNA vaccine that expresses the M. leprae 35 kDa protein both stimulated interferon-gamma (IFN gamma)-secreting T cells in mice, and demonstrated protection against M. leprae-infection of mice.


Assuntos
Vacinas Bacterianas/administração & dosagem , Hanseníase/prevenção & controle , Animais , Modelos Animais de Doenças , Hanseníase/imunologia , Camundongos , Camundongos Endogâmicos , Sensibilidade e Especificidade , Vacinas de Subunidades Antigênicas/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA